Physician
Aurora Health Care Southern Lakes, INC.
Aurora Health Care Southern Lakes, INC. was paid $19.94M by Medicaid between Jan 2018 and Dec 2024, across 322 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoAURORA HEALTH CARE SOUTHERN LAKES, INC.
KENOSHA, WI 53142
KENOSHA, WI 53142
33aNPI1225156888assigned 03/26/2007
33bProvider typeNuclear Medicine Physician
28Total paid$19.94M
24GClaims856,891
24DCodes billed322
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 85,772 | $1.99M | |
| 2019 | 88,641 | $2.04M | |
| 2020 | 79,295 | $1.94M | |
| 2021 | 108,013 | $2.40M | |
| 2022 | 144,276 | $3.28M | |
| 2023 | 194,509 | $4.26M | |
| 2024incomplete | 156,385 | $4.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 34,103 | 30,711 | $2.12M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.2% | 45,831 | 15,853 | $1.63M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.0% | 28,158 | 24,959 | $1.59M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.3% | 11,658 | 9,250 | $1.46M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 14,857 | 13,085 | $855K |
| 80053 | Comprehensive metabolic panel | 3.6% | 38,296 | 31,473 | $718K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.6% | 2,693 | 2,498 | $509K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 7,200 | 6,552 | $469K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 6,088 | 5,582 | $458K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 5,887 | 5,374 | $418K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.0% | 9,949 | 9,165 | $407K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.0% | 21,904 | 8,740 | $400K |
310 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 4,173 | $390K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 3,639 | $344K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.4% | 1,501 | $272K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 42,009 | $267K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 3,473 | $244K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 4,278 | $243K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.2% | 1,978 | $239K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 7,341 | $226K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 3,086 | $218K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.0% | 924 | $206K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.0% | 6,921 | $206K |
| 97161 | <1% | 4,839 | $198K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,770 | $174K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,690 | $165K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,388 | $149K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,448 | $146K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,401 | $143K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,113 | $142K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,583 | $138K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,403 | $132K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,406 | $129K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,646 | $126K |
| 76830 | Ultrasound, transvaginal | <1% | 3,875 | $123K |
| 81025 | <1% | 12,562 | $122K | |
| 84484 | <1% | 11,939 | $118K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,512 | $114K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,515 | $110K |
| 97597 | <1% | 2,626 | $106K | |
| 97162 | <1% | 3,058 | $103K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 359 | $102K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,752 | $102K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,777 | $99K |
| 82077 | <1% | 3,565 | $87K | |
| 93975 | <1% | 2,170 | $86K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,794 | $86K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,397 | $83K |
| 82962 | <1% | 10,107 | $83K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 712 | $81K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,052 | $81K |
| 83880 | <1% | 2,797 | $80K | |
| 93017 | <1% | 2,517 | $80K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,905 | $79K |
| 83690 | <1% | 13,117 | $76K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,101 | $73K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 964 | $64K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,760 | $63K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,760 | $61K |
| G0378 | Hospital observation service, per hour | <1% | 2,645 | $60K |
| 0240U | <1% | 1,619 | $60K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,271 | $58K |
| 81001 | <1% | 15,467 | $58K | |
| 83735 | <1% | 10,842 | $54K | |
| 74018 | <1% | 3,502 | $53K | |
| 84145 | <1% | 2,946 | $52K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,200 | $52K |
| 93971 | <1% | 2,065 | $50K | |
| 84702 | <1% | 2,544 | $49K | |
| 93356 | <1% | 566 | $48K | |
| 76801 | <1% | 2,411 | $46K | |
| 71250 | <1% | 1,684 | $44K | |
| 97165 | <1% | 1,115 | $40K | |
| 86850 | <1% | 1,996 | $38K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 663 | $36K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,388 | $35K |
| 86900 | <1% | 2,547 | $35K | |
| 83605 | <1% | 3,826 | $32K | |
| 72141 | <1% | 513 | $31K | |
| 76536 | <1% | 958 | $31K | |
| 73630 | <1% | 3,190 | $31K | |
| 58661 | <1% | 30 | $31K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,704 | $31K |
| 87081 | <1% | 738 | $30K | |
| 73610 | <1% | 2,370 | $30K | |
| 70496 | <1% | 255 | $29K | |
| 70498 | <1% | 289 | $29K | |
| 73562 | <1% | 2,826 | $27K | |
| 80143 | <1% | 2,171 | $26K | |
| 73221 | <1% | 452 | $26K | |
| 82565 | <1% | 1,305 | $25K | |
| 80179 | <1% | 2,139 | $25K | |
| 94060 | <1% | 940 | $25K | |
| 72100 | <1% | 2,370 | $23K | |
| 62323 | <1% | 161 | $23K | |
| 93798 | <1% | 626 | $22K | |
| 73030 | <1% | 2,014 | $21K | |
| 76770 | <1% | 500 | $21K | |
| 85379 | <1% | 2,504 | $20K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 78 | $20K |
| 94729 | <1% | 1,084 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,660 | $20K |
| 81003 | <1% | 5,849 | $20K | |
| 87210 | <1% | 2,130 | $19K | |
| 87077 | <1% | 1,669 | $19K | |
| 93970 | <1% | 436 | $18K | |
| 87040 | <1% | 1,536 | $18K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 435 | $17K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,310 | $17K |
| 85610 | <1% | 5,271 | $17K | |
| 87070 | <1% | 861 | $16K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 877 | $16K |
| 70486 | <1% | 438 | $14K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,540 | $14K |
| 85730 | <1% | 3,243 | $14K | |
| 64493 | <1% | 98 | $14K | |
| 87186 | <1% | 1,934 | $14K | |
| 76642 | <1% | 371 | $14K | |
| 95816 | <1% | 195 | $13K | |
| 73130 | <1% | 1,436 | $13K | |
| 73110 | <1% | 1,261 | $12K | |
| 29580 | <1% | 267 | $12K | |
| 84703 | <1% | 1,455 | $12K | |
| 64494 | <1% | 103 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,117 | $11K |
| 94726 | <1% | 1,061 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,982 | $10K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,487 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,039 | $10K |
| 74183 | <1% | 106 | $9K | |
| 73502 | <1% | 959 | $9K | |
| 82805 | <1% | 232 | $9K | |
| 81002 | <1% | 271 | $8K | |
| 93351 | <1% | 62 | $8K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 62 | $8K |
| 97116 | <1% | 544 | $8K | |
| 71271 | <1% | 255 | $8K | |
| 85027 | <1% | 1,595 | $7K | |
| 87807 | <1% | 428 | $7K | |
| 70491 | <1% | 75 | $7K | |
| 82550 | <1% | 1,442 | $7K | |
| 12001 | <1% | 95 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 125 | $7K |
| 86901 | <1% | 2,545 | $6K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 15 | $5K |
| 87088 | <1% | 766 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 102 | $5K |
| 93880 | <1% | 174 | $5K | |
| 73140 | <1% | 526 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 326 | $4K |
| 87075 | <1% | 577 | $4K | |
| 90715 | <1% | 332 | $4K | |
| 86140 | <1% | 879 | $3K | |
| 72040 | <1% | 302 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 91 | $3K |
| 73080 | <1% | 336 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 377 | $3K |
| 93225 | <1% | 225 | $3K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 110 | $3K |
| 10005 | <1% | 12 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,308 | $3K |
| 64483 | <1% | 15 | $3K | |
| 78264 | <1% | 34 | $2K | |
| 87205 | <1% | 780 | $2K | |
| 74178 | <1% | 39 | $2K | |
| 99152 | <1% | 297 | $2K | |
| 93308 | <1% | 12 | $2K | |
| 72197 | <1% | 26 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 531 | $2K |
| 93321 | <1% | 12 | $2K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 14 | $2K |
| 76882 | <1% | 45 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 57 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14,331 | $2K |
| 83615 | <1% | 313 | $2K | |
| 73590 | <1% | 328 | $2K | |
| 71101 | <1% | 248 | $2K | |
| 85652 | <1% | 754 | $1K | |
| 80061 | Lipid panel | <1% | 127 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,027 | $1K |
| 88307 | <1% | 238 | $1K | |
| 12011 | <1% | 25 | $1K | |
| 36430 | <1% | 24 | $1K | |
| 97163 | <1% | 44 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,954 | $1K |
| 97802 | <1% | 58 | $1K | |
| 95811 | <1% | 13 | $1K | |
| 92526 | <1% | 49 | $1K | |
| 74019 | <1% | 101 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 48 | $971.78 |
| 82150 | <1% | 174 | $929.74 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 82 | $855.78 |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 13 | $846.75 |
| 84439 | <1% | 126 | $792.25 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $743.81 |
| 82010 | <1% | 106 | $736.17 | |
| 86923 | <1% | 35 | $588.06 | |
| 85014 | <1% | 180 | $563.05 | |
| 84550 | <1% | 156 | $546.16 | |
| 20553 | <1% | 15 | $545.80 | |
| 93325 | <1% | 26 | $509.85 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,647 | $468.80 |
| 76937 | <1% | 128 | $468.50 | |
| 82272 | <1% | 159 | $443.17 | |
| 76870 | <1% | 30 | $433.55 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $392.68 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,098 | $357.00 |
| 88304 | <1% | 278 | $356.40 | |
| 97022 | <1% | 31 | $341.35 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 383 | $324.73 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 422 | $316.14 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $312.80 |
| 96376 | <1% | 2,667 | $309.64 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 23 | $289.09 |
| 36000 | <1% | 887 | $283.74 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 3,495 | $278.21 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,126 | $227.98 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,324 | $211.06 |
| 73564 | <1% | 27 | $208.19 | |
| 74230 | <1% | 14 | $207.62 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,112 | $201.36 |
| 72070 | <1% | 66 | $192.89 | |
| 99001 | <1% | 54 | $187.08 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,295 | $179.09 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 286 | $158.07 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,326 | $156.11 |
| 74022 | <1% | 335 | $156.06 | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $148.76 |
| C1769 | Guide wire | <1% | 2,713 | $147.42 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,405 | $134.83 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,441 | $121.97 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,969 | $121.72 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 20,439 | $121.56 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,973 | $114.57 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,090 | $114.10 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 227 | $112.54 |
| 83550 | <1% | 16 | $103.83 | |
| 84132 | <1% | 39 | $101.04 | |
| 84156 | <1% | 35 | $97.03 | |
| 73660 | <1% | 14 | $94.56 | |
| 84100 | <1% | 33 | $94.37 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,511 | $94.04 |
| 73090 | <1% | 81 | $85.80 | |
| 83540 | <1% | 16 | $76.94 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 474 | $76.23 |
| 80076 | <1% | 12 | $76.13 | |
| 82570 | <1% | 16 | $75.33 | |
| J2704 | Injection, propofol, 10 mg | <1% | 14,375 | $69.92 |
| 87147 | <1% | 12 | $59.28 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,359 | $58.65 |
| 80050 | General health panel | <1% | 154 | $58.02 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,103 | $56.56 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,711 | $46.55 |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,989 | $45.13 |
| 72170 | <1% | 26 | $30.28 | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | <1% | 509 | $11.65 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 272 | $8.80 |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 30 | $6.95 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,329 | $5.45 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,020 | $3.46 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 894 | $1.75 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 838 | $1.22 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 910 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 230 | $0.00 |
| 88342 | 0% | 328 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,287 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 368 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 1,913 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 638 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 55 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 2,602 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 790 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 1,668 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 404 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 161 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 100 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 119 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 786 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 458 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 423 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 12 | $0.00 |
| 80320 | 0% | 27 | $0.00 | |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | 0% | 43 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 28 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 50 | $0.00 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 14 | $0.00 |
| J3590 | Unclassified biologics | 0% | 27 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 13 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 28 | $0.00 |
| 73552 | 0% | 14 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 89 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 57 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 12 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 14 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 371 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 472 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 368 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 937 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,321 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,954 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 625 | $0.00 |
| A4565 | Slings | 0% | 141 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,206 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 451 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 116 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 309 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 81 | $0.00 |
| 88302 | 0% | 39 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 84 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 238 | $0.00 |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 19 | $0.00 |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 83 | $0.00 |
| C1729 | Catheter, drainage | 0% | 54 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 147 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 81 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 12 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 17 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 21 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 12 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 14 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (VP MANAGED HEEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.